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ABSTRACT OF THE DISSERTATION
A Mechanism of Antimicrobial Resistance and a Mitigation Strategy
by
Christopher Bulow
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2018
Professor Gautam Dantas, Chair

The ability to treat infections, perform surgery, and administer immunosuppressants and
chemotherapy depends on effective antibiotics. The emergence and spread of antimicrobial
resistance is far outpacing the development of new therapies 1-3 threatening to thrust medicine
into a post-antibiotic era4. Many mechanisms of antimicrobial action and of antimicrobial
resistance remain poorly understood as drug development struggles to keep pace. As resistance
develops, the human gut serves as a reservoir and provides ample opportunities for resistance
gene transmission between commensal and pathogenic bacteria 5-11. Once resistant organisms
colonize the gut, they can persist for extended durations even without continued antimicrobial
exposure6-12. New approaches are necessary to prevent or reverse colonization with resistant
organisms. This work takes two important steps to addressing the antimicrobial resistance crisis:
1) Understanding an antimicrobial mechanism of action and a corresponding mechanism of
resistance and 2) Developing an approach to prevent or reverse colonization of human hosts with
resistant organisms.

viii

Daptomycin, a broad spectrum antibiotic used for treating multi-drug resistant Grampositive infections, is experiencing clinical failure against important infectious agents including
Corynebacterium striatum, an opportunistic pathogen and skin commensal. The recent transition
of daptomycin to generic status is projected to dramatically increase availability, use, and clinical
failure. Here we confirm the genetic mechanism of high-level daptomycin resistance (HLDR,
MIC > 256 µg/mL) in C. striatum, which evolved within a patient during daptomycin
therapy. This work demonstrates that loss of function mutation in pgsA2 and the loss of
membrane PG is necessary and sufficient to produce high-level resistance to daptomycin in C.
striatum. This elimination of PG and the absence of additional compensatory changes support the
conclusion that PG is the target of daptomycin. This work highlights the importance of
understanding how different bacterial species respond to lipopeptide antibiotics. Drugs that target
membrane components may vary in efficacy by species due to differing abilities of species to
alter or remove various membrane components.
Strategies to prevent infection by multidrug-resistant organisms (MDROs) are scarce;
however, autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal
MDRO expansion. AutoFMT involves banking one’s feces during a healthy state for later use in
restoring gut microbiota following perturbation. In this pilot clinical trial involving 10 healthy
participants, autoFMT was safe and well tolerated in the ten participants evaluated. The trial also
evaluated the effects of amoxicillin-clavulanic acid (amox/clav) exposure and the ability of
autoFMT to restore the microbiome. Both autoFMT and saline control restored metabolic
capacity and resistance gene levels, but additional work is necessary to determine its ability to
restore phylogeny. Importantly, metabolic capacity was perturbed following amox/clav even in
cases where gross phylogeny remained unchanged.
ix

Chapter 1
Introduction
1.1 Antimicrobial Resistance
The emergence and spread of antimicrobial resistance is far outpacing the development of
new therapies1-3. An ever growing number of bacterial infections are resistant to clinical
antimicrobials of choice2,13. Every year resistant infections are responsible for over 700,000
deaths globally4. This figure is predicted to reach 10 million deaths per year by 2050 and the
World Health Organization warns that medicine is approaching a post-antibiotic era4. This will
undermine the very foundations of modern medicine by limiting our ability to treat infections,
perform surgery, and administer immunosuppressants and chemotherapy.
Antimicrobial resistance genes and the pathogenic or commensal organisms that carry
them colonize body sites and environmental surfaces. This allows continued spread to new
hosts14.The human gut is one important reservoir of such resistance genes and provides ample
opportunities for resistance gene transmission between commensal and pathogenic bacteria5-11.
Once resistant organisms colonize the gut, they can persist for extended durations even without
continued antimicrobial exposure6-12. New approaches are necessary to prevent or reverse
colonization with resistant organisms.
In an effort to mitigate the impending antimicrobial resistance crisis, two steps can be
taken: 1) Understanding antimicrobial mechanisms of action and corresponding mechanisms of
resistance and 2) Developing approaches that prevent or reverse colonization of human hosts
with resistant organisms.
1

1.2 Mechanisms of Daptomycin Action and Resistance
Understanding mechanisms of antimicrobial resistance can aid in designing more
effective therapies. An important first step is clarifying the mechanisms by which current
antimicrobials kill or inhibit bacteria. This work brings much needed clarity to the daptomycin’s
antimicrobial mechanism of action and provides a detailed explanation of high-level resistance
observed in the clinic.

1.2.1 Daptomycin
Daptomycin is a last-resort antibiotic reserved for treatment of severe gram-positive
infections. This non-lytic15 lipopeptide antibiotic has activity against both stationary and log
phase Gram-positive bacteria16 such as Staphylococcus aureus, Enterococcus faecium, and
Corynebacterium striatum17-19. It is also known that daptomycin exhibits off target binding to
eukaryotic cells, leading to toxic effects in humans 20. For this reason, daptomycin was originally
abandoned by during the development phase21. As the clinical need for effective antimicrobials
grew, developers revisited daptomycin despite the risks of toxicity21. Furthermore, the maximum
approved dose of daptomycin has been steadily increased to treat more infections20.
Much work has been performed to elucidate daptomycin’s mechanism of action since its
approval for clinical use in 200321-23 but some key questions remain. It is known that daptomycin
forms a complex with Ca2+ and integrates into bacterial membranes leading to K +, Mg2+, and
ATP leakage and cell death24,25. Although this body of work and recent reports of resistance
implicate phosphatidylglycerol (PG) as the target of daptomycin, the drug’s precise molecular
target and mechanism of action has remained largely unproven23,26. These aspects of mechanistic
activity are critical to understanding resistance and eventually designing the next generation of
2

lipopeptide antibiotics. Conversely, resistance provides a tool for understanding mechanism of
action.
Unfortunately, even careful stewardship of daptomycin has not prevented resistance from
emerging. Most commonly, low-level resistance is seen in Staphylococcus aureus, which is not
unexpected given that daptomycin is commonly used to treat Methicillin-resistant
Staphylococcus aureus (MRSA) infections27. Additionally, there have been reports of high-level
resistance in other gram-positive bacteria, most notably the skin commensal C. striatum28.
Stepwise accumulation of mutations has been responsible for low (Minimum Inhibitory
Concentration, MIC: 2-4 µg/ml) and intermediate (MIC: 4-8 µg/ml) daptomycin resistance in
Staphylococcus aureus over weeks of treatment29-37. For example, in Staphylococcus aureus
single nucleotide polymorphisms (SNPs) in the yycFGHI operon have resulted in 2-6-fold
increases in daptomycin resistance through cell wall thickening and alteration of membrane
charge30-35. Membrane charge alteration occurs by increased lysinlyation of PG resulting in more
positive surface charge27,38,39. It has been suggested that this increased surface charge repels the
positively charges Ca2+ daptomycin complex27,38,39. Additional mutations that alter lipid
translocation, decrease membrane fluidity, and thicken the cell wall have led to low-level
daptomycin resistance32,36. Importantly, these low and intermediate resistance mutations are lost
when daptomycin selective pressure is removed37.
While low and intermediate levels of daptomycin resistance have been observed in
Staphylococcus aureus, high levels of resistance have been observed in Bacillus subtilis and
more recently in Corynebacterium. While resistance in Staphylococcus can occur through
increased lysinlyation this process has not been reported in Bacillus or Corynebacterium. In
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2011, Bacillus subtilis nearly 30 times more resistant (MIC = 27.5 ug/mL) to daptomycin than
wild type was selectively evolved in vitro by serial passage through increasing concentrations of
daptomycin. Alarmingly, this strain also displayed resistance to vancomycin, moenomycin, and
bacitracin40. Even so, Bacillus subtilis is a low-pathogenicity model organism and this level of
resistance were observed in vitro40. B. subtilis was found to harbor SNPs in 44 genes, including
predicted reduction/loss of function mutations in phosphatidylglycerol synthase A (pgsA),
transmembrane protein responsible for phosphatidylglycerol (PG) synthesis40,41. Characterization
of the lipid membrane revealed a reduction in PG content from 30% in the wild-type to 10% in
the resistant mutant. This is an important parallel to the loss of PG through lysinlyation in lowlevel Staphylococcus aureus resistance. In vitro attempts to knock out pgsA alone were
unsuccessful perhaps due to essentiality of some level of PG in B. subtilis40.
Aside from reports of Streptomyces species capable of inactivating daptomycin
enzymatically42,43, clinical isolates have become resistant to daptomycin through membrane
alteration26,40,41. Specifically, studies of daptomycin’s target to date highlight the importance of
PG for daptomycin activity26,40,41. A recent comparative genomic and lipidomic study of
Staphylococcus aureus, Corynebacterium

striatum, and Enterococcus faecalis indicated

mutations in PG synthase and subsequent lack of PG synthesis confers daptomycin resistance26.
Recently, there have been increased reports of even higher-level daptomycin resistance
(4000 fold increase in resistance) in a number of clinical pathogens, including viridians group
Streptococci44, Enterococcus faecium19, and Corynebacterium striatum28. This high-level
daptomycin resistance (HLDR)—defined here as a minimum inhibitory concentration (MIC) 
256 in Corynebacterium striatum is the subject of Chapter 2. The findings presented here are
consistent with a complete loss of PG from the membrane without additional compensatory
4

changes. Understanding of the mechanism underlying such high-level resistance are expected to
aid in design of more effective lipopeptide antibiotics. Daptomycin resistance and accompanying
clinical failures are expected to expand as daptomycin transitions to generic status and clinical
use increases45.

1.2.2 Corynebacterium striatum
Corynebacterium striatum is a Gram-positive bacterium which can reside as a
commensal organism on the skin46. However, it has become a growing threat to hospital systems
and patients as an opportunistic pathogen with the ability to rapidly evolve high-level
daptomycin resistance47. Left unchecked, Corynebacterium striatum has the potential to become
an epidemiological scourge. Corynebacterium striatum has been associated with bacteremia,
endocarditis, urinary tract, wound, respiratory, central line, medical device and hardware
infections28,48-54. HLDR was first observed in C. striatum, in a patient with native valve
endocarditis in 201255. Again in 2014, a clinical laboratory reported evolution of HLDR C.
striatum in a patient with an infected left ventricular assist device, during 17 days of daptomycin
therapy28.
C. striatum poses such a serious threat in part due to its ability to rapidly and completely
remove PG from its outer membrane, demonstrated here. This work establishes a genetic,
transcriptomic, lipidomic and biochemical understanding of how C. striatum rapidly evolves
high-level daptomycin resistance. It demonstrates that loss of function mutations in pgsA2 result
in reduced membrane PG content from ~45% to <1%. This mechanism is notably distinct from
previously described resistance in S. aureus and Streptomyces spp29-36 in that PG can be nearly
eliminated without apparent compensatory mechanisms. This elimination of PG and the absence
of additional compensatory changes support the conclusion that PG is the target of daptomycin.
5

This work highlights the importance of understanding how different bacterial species respond to
lipopeptide antibiotics. Drugs that target membrane components may vary in efficacy by species
due to differing abilities of species to alter or remove various membrane components.

1.2.3 Autologous Fecal Microbiota Transplantation
The spread of multidrug resistance among pathogenic organisms threatens the efficacy of
antimicrobial treatment options56. The human gut serves as a reservoir for many drug resistant
organisms and their resistance genes and perturbation of the gut microbiome by antimicrobial
exposure can open metabolic niches to resistant pathogens. Once established in the gut,
antimicrobial resistant bacteria can persist even after antimicrobial exposure ceases.
Despite the growing antimicrobial resistance threat, the factors that allow resistant
pathogens to colonize the gut remain largely unknown. Furthermore, there are no established
methods to effectively reverse the effects of antimicrobial exposure on commensal or pathogenic
bacteria.
Several strategies have been proposed for mitigating the threat of resistance but each
carries risk. These strategies include targeted antimicrobial therapy, single species probiotics,
and allogeneic fecal microbiota transplantation (alloFMT). This work proposes and evaluates
autologous fecal microbiota transplantation (autoFMT) as a method of limiting gastrointestinal
multidrug resistant organism (MDRO) expansion. AutoFMT involves banking one’s feces during
a healthy state for later use in restoring gut microbiota following perturbation (Figure 1-1).

6
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Figure 1-1: AutoFMT Banking a healthy participant’s feces for later use in restoring the fecal
microbiome to a healthy and balanced state after perturbation such as antimicrobial treatment.
Targeted delivery of antimicrobials has been proposed as a method of limiting resistance
gene selection. For example, using non-absorbable broad-spectrum antimicrobials such as
rifaximin confines the drug to the gut and may prevent systemic resistance selection57. However,
this practice still leads to resistance selection in the gut and allows opportunistic pathogens to
gain access in this critical body habitat58. From there, they can spread to the rest of the body
microbiome and rapidly to other human hosts 59.
The ingestion or delivery of microbial species as probiotics to confer health benefit dates
back to ancient times and has been refined gradually to the probiotic approaches familiar today 60.
Strains of microbes largely belonging to the genera of Lactobacillus, Bifidobacterium,
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Saccharomyces, Enterococcus, and Escherichia are administered with the intention of displacing
or preventing colonization with pathogens 61. Due to the wide variation in microbial community
structure between individuals62, the safety and efficacy of these probiotics varies greatly63,64.
Furthermore, treatments limited to one or several species cannot protect the many diverse niches
in the gut from pathogen or MDRO colonization65.
A healthy fecal microbiome defends against pathogen and MDRO invasion through
colonization resistance66. Fecal microbiota transplantation (FMT) has been proposed as a method
of restoring the microbiome to a healthy state after perturbation67. Unlike single species
probiotics, FMT can fill many niches of the gut microbiome. By displacing infectious or resistant
microbes, the FMT can restore species diversity, antimicrobial susceptibility, and colonization
resistance67. FMT from healthy allogeneic donors (alloFMT) has been successful in treating
Clostridium difficile infection (CDI)67,68. Some studies indicate patients who receive alloFMT for
CDI may have a reduction in MDROs in feces and experience less risk of infection 69-75.
However, this approach has been found to allow transmission of resistance genes from donor to
recipient76. Donor feces may also transmit pathogens which are being asymptomatically harbored
by the allogeneic donor. Additionally, microbiota structure varies significantly between
individuals and a poor donor-recipient match may lead to dysbiosis or FMT failure77-80.
AutoFMT has the potential to restore the gut to a healthy state while avoiding the risks of
donor resistance genes and donor-recipient mismatch. AutoFMT involves storage of a healthy
person’s fecal material for later use to restore their own gut microbiota after perturbation, such as
antimicrobial use. Bolstering the commensal microbiome by autoFMT following exposure to
antimicrobials may be effective at combating colonization with pathogens and MDROs 71.

8

AutoFMT is predicted to have a more desirable safety profile compared to alloFMT because the
feces originated from the participant and was collected during a healthy state.
The pilot clinical trial described here evaluated the effect of amoxicillin-clavulanic acid
(amox/clav) exposure and autoFMT on gastrointestinal microbiome taxonomic composition,
resistance gene content, and metabolic capacity. AutoFMT was safe and well tolerated in the ten
participants evaluated. Shotgun metagenomic sequencing allowed for analysis of genes beyond
the taxonomic data available through 16S sequencing. Importantly, metabolic capacity was
perturbed even in cases where gross phylogeny remained unchanged. This underscores the need
to understand the effects of antimicrobial therapy on the microbiome in greater detail.
These findings highlight the gaps in current knowledge regarding the effects of
antimicrobials on the gut microbiome and the efficacy of mitigation strategies. Due to cost and
sequencing constraints microbiome studies have primarily relied on 16S rRNA analyses of
bacterial taxonomic composition and diversity81-84. While such studies have been transformative
in demonstrating how well taxonomic compositions match between FMT donors and recipients
over time, they are generally not designed to illuminate functional changes in the
microbiome83,84. Accordingly, complementary approaches are required to enable a higher
resolution understanding of the impact of FMTs on the composition, dynamics, and transmission
of resistance genes and metabolic capacity encoded by the microbiome. Shotgun sequencing
provides the ability to identify resistance and metabolically linked genes. Functional
metagenomic selection and sequencing will allow for even more detailed analysis of functional
shifts in the microbiome.

9

To prevent the arrival of a post-antibiotic era4 we must better understand the mechanisms
of action and collateral effects of antimicrobials. The work described here makes progress
toward understanding mechanisms of action and high-level resistance of daptomycin, a key
clinical antimicrobial. Furthermore, this work identifies important post-antimicrobial shifts in gut
microbiome metabolic capacity that would have been overlooked by traditional 16S rRNA
analyses of the microbiome. The struggle against antimicrobial resistance predates humans and
finds its origins in the ongoing war between fungi and bacteria85. Our strategic advantage in this
conflict lies in better understanding our microbial foes and our antimicrobial tools.

10

Chapter 2
Mechanism of High-Level Daptomycin
Resistance in Corynebacterium striatum
Collaboration Statement
This work was performed a collaboration between Christopher Bulow, Nicholas K.
Goldner, Kevin Cho, Meghan Wallace, Fong-Fu Hsu, Gary Patti, Carey-Ann Burnham, Paul
Schlesinger, and Gautam Dantas. C.B. and N.K.G designed, performed experiments, analyzed
data and wrote the manuscript. K.C. and M.W. performed experiments and analyzed data. FF.H,
G.P., CA.B., P.H.S. and G.D. designed experiments, analyzed data, and wrote the manuscript.

2.1 Abstract
Daptomycin, a last line of defense antibiotic for treating Gram-positive infections, is
experiencing clinical failure against important infectious agents including Corynebacterium
striatum. The recent transition of daptomycin to generic status is projected to dramatically
increase availability, use, and clinical failure. Here we confirm the genetic mechanism of highlevel daptomycin resistance (HLDR, MIC > 256 µg/mL) in C. striatum, which evolved within a
patient during daptomycin therapy, a phenotype recapitulated in vitro. In all 8 independent cases
tested, loss of function mutations in phosphatidylglycerol synthase (pgsA2) were necessary and
sufficient for high-level daptomycin resistance. Through lipidomic and biochemical analysis we
demonstrate that daptomycin’s activity is dependent on membrane phosphatidylglycerol (PG)
concentration. Until now, the verification of PG as the in vivo target of daptomycin has proven
11

difficult since tested cell model systems were not viable without membrane PG. C. striatum
becomes high-level daptomycin resistant by removing PG from the membrane and changing
membrane composition to maintain viability. This work demonstrates that loss of function
mutation in pgsA2 and the loss of membrane PG is necessary and sufficient to produce high-level
resistance to daptomycin in C. striatum.

2.2 Introduction
Current trends in rapidly emerging antimicrobial resistance and decreasing drug
development require mitigation1-3. Antibiotic resistant infections claim over 700,000 lives
globally, and this annual toll is predicted to swell to 10 million deaths a year by 2050 without
significant intervention. A growing number of bacterial infections are already resistant to nearly
all first-line antibiotics2,13. Physicians are forced to use “last-resort”, broad-spectrum antibiotics
more frequently, and resistance to even these carefully safeguarded drugs has emerged 86,87.
Daptomycin is one such last-resort non-lytic15 lipopeptide antibiotic, effective against both
stationary and log phase Gram-positive bacterial pathogens16 including Staphylococcus aureus,
Enterococcus faecium, and Corynebacterium striatum17-19. Daptomycin integrates into the
bacterial cell membrane in a Ca2+ dependent manner, causing membrane dysfunction that leads
to K+, Mg2+, and ATP leakage and cell death24,25. Very low levels of resistance were observed
during the early phase of daptomycin’s clinical use. Regrettably, recent clinical reports of
treatment failures have emerged of pathogens exhibiting >2000-fold increases in daptomycin
resistance28,44,88, often over rapid time-scales (hours to a few days of treatment), which are
beginning to challenge daptomycin’s efficacy. These failures are expected to expand as
daptomycin transitions to generic status and clinical use increases 45.

12

C. striatum is an emerging opportunistic pathogen that colonizes the skin much like S.
aureus. C. striatum’s ability to rapidly transition from daptomycin susceptible to resistant poses
a serious epidemiological threat to our healthcare system47. This work establishes a genetic,
transcriptomic, lipidomic and biochemical understanding of how C. striatum rapidly evolves
high-level daptomycin resistance. This mechanism is notably distinct from previously described
resistance in S. aureus and Streptomyces spp.29-36 In S. aureus, low-level, step-wise
accumulations in resistance phenotypes are responsible for low (Minimum Inhibitory
Concentration, MIC: 2-4 µg/ml) and intermediate (MIC: 4-8 µg/ml) daptomycin resistance29-36.
The majority of these observations come from pathogenic S. aureus, which was the first
approved therapeutic target for daptomycin29. Accumulation of multiple single nucleotide
polymorphisms (SNPs) in the yycFGHI operon in S. aureus has resulted in 2-6-fold increases in
daptomycin resistance through cell wall thickening and alteration of membrane charge 30-35.
Increases in positively charged membrane phospholipids, which reduces the affinity of the Ca2+conjugated daptomycin for the surface membrane increased the MIC. Additionally, mutations
that alter lipid translocation, decrease membrane fluidity, and thickening of the cell wall have led
to low-level (3-6 fold) increases in daptomycin resistance32,36. Mutations associated with the
above physiological changes in pathogenic S. aureus have all led to small stepwise increases (2-6
fold) in resistance over long periods of time (weeks of treatment) and lose resistance to
daptomycin when no longer under daptomycin’s selection pressure37. In contrast, some
environmental Streptomyces species have been shown to inactivate daptomycin42,43
enzymatically; clinical isolates have not used this mechanism to date.
The first report of higher levels (~20-fold over wild-type) of daptomycin resistance come
from laboratory adaptive evolution experiments with the non-pathogenic, soil bacterium,
13

Bacillus subtilis40. Daptomycin resistant B. subtilis was found to harbor SNPs in 44 genes,
including predicted reduction/loss of function mutations in phosphatidylglycerol synthase A
(pgsA), an essential enzyme for phosphatidylglycerol (PG) synthesis40,41. Characterization of the
lipid membrane revealed a reduction in PG content from 30% in the wild-type to 10% in the
resistant mutant. Consistent with the lack of complete ablation of PG in the membrane, attempts
to knock out pgsA alone genetically were not successful due to presumed essentiality of PG in B.
subtilis40. Nevertheless, studies of daptomycin’s target to date corroborate in vivo the importance
of PG in daptomycin activity26,40,41. Indeed, a recent comparative genomic and lipidomic study of
S. aureus, C. striatum, and Enterococcus faecalis indicated mutations in PG synthase and
subsequent lack of PG synthesis confers daptomycin resistance26.
Over the past few years, there has been a steady increase in reports of even higher-level
daptomycin resistance (4000 fold increase in resistance) in a number of clinical pathogens,
including viridians group Streptococcus44, Enterococcus faecium19, and C. striatum28. This highlevel daptomycin resistance (HLDR)—defined here as a minimum inhibitory concentration
(MIC)  256 g/ml daptomycin—was first observed in C. striatum, in a patient with native valve
endocarditis in 201255. In 2014, a clinical laboratory reported in vivo evolution of HLDR C.
striatum in a patient with an infected left ventricular assist device, during 17 days of daptomycin
therapy28. Evolution of HLDR was recapitulated in vitro in 100% of tested C. striatum isolates
(n=50) after 24 hours of daptomycin exposure89. C. striatum is a Gram-positive bacterium which
typically resides as a commensal organism on the skin46. However, it has become a growing
threat to hospital systems and patients as an opportunistic pathogen. Indeed, C. striatum has been
associated with a plethora of infection types over the past 20 years including bacteremia,
endocarditis, urinary tract, wound, respiratory, central line, medical device and hardware
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infections28,48-54. Here we use a combination of comparative genomics, transcriptomics,
lipidomics, electron microscopy, and biochemical lipid and liposome characterization to
elucidate the mechanism of HLDR evolved in C. striatum both within patients and in vitro. We
demonstrate that loss of function mutations in pgsA2 result in reduced membrane PG content
from ~45% to <1%. This shift and the absence of additional compensatory changes support the
conclusion that PG is the target of daptomycin. This work highlights the ability of bacterial cells
to manipulate membrane lipid composition to effectively evade lipid targeted lipopeptides.

2.3 Results
2.3.1 PG Synthase Mutations in HLDR C. striatum Strains
All cases of evolved high-level daptomycin resistance (HLDR) in C. striatum that were
tested (Figure 2-1 and Supplemental Table 2-1) had a predicted loss of function mutation in PG
synthase. We performed whole genome sequencing of eight pairs of in vivo and in vitro evolved
HLDR C. striatum isolates (n = 16), and found pgsA2 to be the only gene mutated consistently in
all HLDR mutants. The affected gene encodes PG synthase, responsible for converting CDPDAG to PG (Figure 2-2a). The mutations observed include coding changes at universally
conserved sites (Figure 2-1b), the dimer interface (Figure 2-1c), the active site (Figure 2-1d), and
those leading to premature stop codons (Figure 2-1e). Each of these mutations is predicted by
snpEFF90,91 and PHYREII92,93 homology modeling to result in loss of PG synthase activity.
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Figure 2-1: All HLDR isolates have predicted nonfunctional mutations in pgsA2 a, Structure
of PG synthase monomer with mutations in conserved sites overlaid. b, mutation in CDP alcohol
phosphatidyl transferase active site conserved across species. c, mutation in the dimer interface
domain. d, mutation in substrate binding pocket. e, premature stop mutations predicted to
produce truncated products.
We found no additional SNPs in the C. striatum genomes predicted to alter cellular
biosynthetic processes in potential compensation for PG synthase loss of function. In B. subtilis,
loss of just pgsA2 (PG synthase) was lethal and compensatory mutations were necessary for cell
survival40 leading us to consider whether additional mutations may also be required for HLDR in
C. striatum.
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A total of 8 additional non-synonymous SNPs in biosynthetic pathways were detected in
the in vivo evolved isolate (Supplemental Figure 2-1). Aside from the pgsA2 mutation, no SNPs
in biosynthetic pathways were detected in the in vitro evolved HLDR isolates. This is consistent
with the longer time between susceptible and resistant isolate collection in vivo (17 days) versus
in vitro (24 hours). The remaining SNPs in genes not related to biosynthesis did not cluster in
similar pathways. No consistent genetic change besides the loss of function mutation in pgsA is
predicted to result in compensatory changes that would contribute to membrane viability or
HLDR in C. striatum.
Each of the parent daptomycin susceptible C. striatum isolates were derived from
different patients, and the in vivo and in vitro HLDR phenotypes were evolved independently.
This breadth of evolution events in C. striatum isolates obtained from infected patients provides
a robust, clinically relevant cohort for assessing mutations necessary to daptomycin resistance.
Accordingly, comparative genomics indicates that loss of function SNPs in pgsA2 encoding PG
synthase are the only genomic change necessary for HLDR and no additional mutations are
required to maintain resistant cell viability. In a recent report of evolved xenobiotic resistance in
Corynebacterineae (the suborder which includes Corynebacterium) minimal genetic mutations
were observed between susceptible and resistant pairs, but large-scale transcriptomic changes
were found to explain the change in phenotype26,94. Accordingly, we tested whether whole cell
transcriptional changes were potentially responsible for compensating the loss of PG synthase
function and stabilization of the membrane in HLDR C. striatum.
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2.3.2 Minimal Transcriptional Changes in HLDR C. striatum
No significant transcriptional changes were detected in biosynthetically linked genes in
clinically evolved HLDR in C. striatum (Figure 2-2c, Supplemental Figure 2-2b). We compared
the transcriptomes of the WP1a (index, daptomycin susceptible) and RP1b (HLDR evolved in
the patient) strains grown in cation-adjusted Mueller-Hinton broth (CAMHB) to exponential
phase in biological triplicate. Even the largest magnitude transcriptional changes did not exceed
+/- 85%, much smaller than transcriptomic changes typically associated with phenotypic
alteration94. Expression changes in genes related to phospholipid biosynthesis were small in
magnitude (less than 25%) and not significant. Furthermore, most transcriptomic changes
observed occurred in transposase genes and hypothetical proteins of viral origin. The greatest
magnitude change in biosynthetically linked gene expression was the LGFP repeat protein
transcript detected at levels 1.302-fold (~30%) greater in the HLDR strain. This small change is
not predicted to contribute to resistance or viability. PgsA2 expression levels changed by only
0.981-fold (not significant) in the HLDR strain, further indicating that the HLDR phenotypic loss
of PG is due to loss-of-function mutations rather than reduced expression. Lack of transcriptional
alterations prompted us to interrogate the membrane composition of daptomycin susceptible and
HLDR C. striatum strains using a comparative lipidomics approach, as we hypothesized that the
HLDR phenotype resulted from the disruption of PG synthase activity, which effectively
removes PG from the membrane (Supplemental Figure 2-3b).
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Figure 2-2: Lipid metabolism pathway of phosphatidylglycerol, observed SNPs and relative
abundance changes of key lipids between WT and HLDR isolates The PG (a) and CL (b)
lipid synthesis pathways were constructed with KEGG. 8 WT and HLDR isolate paired genomes
were compared and nonsynonymous single nucleotide polymorphisms identified. The
metabolites names and structures are on the left, with key lipids colored in red and green. R1
represents the 16:0 carbon chain and R2 represents the 18:1 carbon chain. The enzyme
nomenclature for each enzymatic step and their corresponding genes are located next to the
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appropriate synthesis arrow. SNP mutations for each enzyme/gene unit are to the far right with
the number of mutations out of the 8 HLDR isolates, unless no mutations were present in any of
the isolates. Except for pgsA2, none of the lipid synthesis genes for PG have SNPS. On the left
side, black bars indicate the functional completeness of the PG synthesis pathway. WT proceeds
through the entire synthesis pathway producing PG, while HLDR ends at the production of CDPDAG. The green color of the lipid CDP-Dag indicates a 543-5946-fold buildup of that metabolite
in the HLDR isolates compared to WT. The Red color of PG and cardiolipin indicates a
reduction of that metabolite in the HLDR isolates compared to WT with a 369-1990-fold
reduction in PG. c, Expression levels of genes involved in lipid synthesis pathways were not
significantly altered in HLDR (p>0.05). Expression levels of the housekeeping genes rpoA and
gyrA were also not significantly altered (p>0.05).

2.3.3 Lipidomics Reveals Loss of Phosphatidylglycerol in the Membrane
We found that loss of PG synthase function leads to removal or at least a > 360-fold
reduction of membrane phosphatidylglycerol (PG) content in HLDR C. striatum isolates.
Analysis by mass spectrometry of whole-cell membrane lipid content of four pairs of
daptomycin susceptible and HLDR isolates, which represent each of the four types of predicted
loss-of-function pgsA2 mutations (Figure 2-2 b-e and Supplemental Table 1) reveals loss of PG.
In each isolate pair, PG detection was 369-1990-fold (p ≤ 0.0001) lower in the evolved HLDR
isolates than in the daptomycin susceptible ancestor (Figure 2-3a), levels in the HLDR isolates
which are indicative of complete removal of PG in the membrane, resulting in the HLDR
phenotype. In addition to PG, cardiolipin (CL, a derivative of PG) was the other lipid absent in
the HLDR isolates (Figure 2-3a, c). However, CL was also absent in the daptomycin susceptible
WP1a isolate, and because of subsequent in vitro data, we posit it is not the primary target of
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daptomycin. We also found no lipidomic evidence that the sn-1/sn-2 fatty acyl groups in PG is
being modified to shield it from daptomycin binding hypothesized in low-level resistant S.
aureus isolates 95-98. Conversion of PG to CL, a proposed mechanism of daptomycin resistance 99,
also does not contribute to the C. striatum HLDR mechanism, since CL is absent in the HLDR
strains (p ≤ 0.0001) (Figure 2-3c). PG synthase converts CDP-Dag, a biosynthetic precursor of
PG, into phosphatidyl glycerol (Figure 2-2a). In the absence of PG synthase, we expected CDPDag to either be utilized in a secondary lipid synthesis pathway or to accumulate in the cell. In
support of the latter hypothesis, we found that CDP-Dag levels are significantly (543-5946-fold;
p ≤ 0.0001) higher in HLDR isolates over their WT counterparts (Figure 2-2a and Figure 2-3b).
PG synthase in HLDR strains across mutation types is nonfunctional (Figure 2-1b-e and Figure
2-2a) and no compensatory changes are being made in the PG biosynthesis pathway (Figure 22a-c, Supplemental Figure 2-2), enabling high-level CDP-Dag accumulation (Figure 2-2a and
Figure 2-3).
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Figure 2-3: Lipidomic comparison of WT and resistant paired isolates across mutation types
a-e, the y-axis represents the relative abundance of the important phospholipid between the WT and
HLDR isolates. WT-HLDR pairs are associated by color with WT represented by solid block colors
and HLDR represented by black striped colors. The lipid that is most abundant in the WT or HLDR
isolate has been normalized to 100. Fold changes, where calculable, are listed above the WT and
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HLDR comparisons; fold change was calculated using (b-a)/a, where ‘b’ is the largest value and
‘a’ is the smallest to maintain a positive number. The structures of the lipid are directly to the right
of the graph with R1 = 16:0 carbon chain and R2 = 18:1 carbon chain. Statistical analysis was
performed with 1-way anova and every column was means compared p  0.05 (*), p  0.01 (**), p
 0.001 (***), p  0.0001 (****).
Until recently, determining the in vivo target of daptomycin had been challenging
because it was biologically untenable to remove PG from the membrane of model Gram-positive
bacteria without cell death88,100. A recent study26 corroborates that C. striatum appears to
uniquely compensate for the complete removal of PG in its membrane by increasing the
proportion of two other lipids in the membrane: PI (Figure 2-3e and Supplemental Figure 2-3a,
b) and glucuronosyl diacylglycerol (Glua-Dag) (Figure 2-3d). PI is 1.6-5.3-fold higher (p ≤
0.0001 and p ≤ 0.001) in HLDR over WT (Figure 2-3e and Supplemental Figure 2-3a) and GluaDag is 5.5-23.0-fold higher (p ≤ 0.0001 and p ≤ 0.01) in HLDR over WT (Figure 2-3d). We
demonstrate that the previously proposed mechanisms of daptomycin resistance which include
altering membrane fluidity, leaflet organization, and morphology do not contribute to HLDR in
C. striatum, as the lipid membrane composition changes in the HLDR isolates do not visibly
alter the membrane (by transmission electron microscopy, Supplemental Figure 2-4a) or charge
(by zeta potential, Supplemental Figure 2-4b) compared to daptomycin susceptible counterparts.
These data affirm that PG is the in vivo target of daptomycin and loss of PG due to nonfunctional PG-synthase is necessary and sufficient for the HLDR phenotype.
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2.3.4 Surface Plasmon Resonance Indicates PG is the Preferred Target of
Daptomycin
In support of our genomic and lipidomic conclusions, we performed a structure-function
analysis of PG, which we show is the target of daptomycin and is necessary and sufficient for
daptomycin activity in vitro. By combining Surface Plasmon Resonance (SPR), which measures
binding. and carboxyfluorescein liposome stability assays (CFLSA) studies, which measure
activity, we are able to understand the structural interactions of daptomycin with PG. We use 200
nm artificial liposomes of relevant membrane lipid compositions to determine these
relationships. Four lipid species—PG, CL, phosphatidic acid (PA) and phosphatidylcholine (PC)
(Figure 2-4f and Supplemental Figure 2-3)—were tested for daptomycin binding affinity. PI and
Glua-Dag are both found in WT and HLDR isolates, and we did not test them in the next set of
experiments because our lipidomics analysis indicated they are not the in vivo targets of
daptomycin. Three types of liposomes of defined composition were assembled, comprised of PG,
CL, and PA combined at a 1:1 molar ratio with PC, and compared with homogeneous PC-only
liposomes. Daptomycin showed a significantly higher affinity to PG liposomes (p ≤ 0.0001 and p
≤ 0.001) than any of the other lipids tested (Figure 2-4). PG has been hypothesized to be an in
vitro target of daptomycin due to its charged phosphate, however, the lack of binding to PC and
minimal binding to PA (Figure 2-4e) indicate that the negatively charged phosphate plays a
subordinate role in daptomycin binding. Additionally, when the fatty acyl groups are restricted to
the bilayer surface plane, as they are in CL, daptomycin binds with much lower affinity (Figure
2-4a-e). When the phosphatidyl-sn-glycerol-3-phosphate glycerol head group is accessible, as it
is with PG, the daptomycin binds more efficiently (Figure 2-4a-e). Also, the daptomycin binding
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to the 1:1 PG liposomes appears to saturate with daptomycin above 20 μg/ml indicating that PG
is acting as a binding site for the daptomycin (Figure 2-4e). Accordingly, we would expect
daptomycin activity to correlate with the binding of PG, CL, PA, and PC, and we tested this
through a carboxyfluorescein liposome stability assay (CLFSA).
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Figure 2-4: Daptomycin binding across concentrations and liposome content a-e, The y-axis
plots the normalized binding of daptomycin at varying concentration ratios to liposomes. The x-axis
shows the type of liposomes tested, which include 1:1 equimolar ratios of PG, PA or CL to PC and
a control liposome made entirely of PC. e, demonstrates stepwise increases in daptomycin binding
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to PG. Statistical analysis was performed with 1-way anova and every column was means
compared, p  0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****).

2.3.5 CFLSA Indicates PG is Necessary and Sufficient for Daptomycin
Activity
We found that presence of PG in the bacterial membrane correlates with daptomycin’s
bactericidal activity. Carboxyfluorescein liposome stability assays (CLFSA) confirmed PG’s role
in daptomycin activity in vitro. Liposomes were generated as above in the presence of selfquenching carboxyfluorescein. Daptomycin is added and interacts with the liposome membrane,
releasing and diluting the carboxyfluorescein, which is then unquenched in the buffer producing
dramatically increased fluorescence101. Daptomycin had higher activity against PG containing
membranes in all cases (Figure 2-5a-f) and acts in a concentration dependent manner against
both PG and PA (Figure 2-5f). Even though PA had lower binding affinity to daptomycin than
CL (Figure 2-4e), daptomycin was more active against PA than it was against liposomes
containing CL where there are no available glycerol-3-phosphates extending from the membrane
surface for daptomycin binding (Figure 2-5a, d). This is consistent with the observed PG to CL
daptomycin activity relationship. Furthermore, this suggests to us that the larger (4 alkane chain
CL) suppresses daptomycin’s integration with membrane structure that is necessary for increased
permeability in the CFLSA assay inhibiting daptomycin activity. We observed a reduction in
daptomycin activity in liposomes that contain CL even though they have a higher binding
affinity than PA and PC (Figure 2-4e and Figure 2-5a-f). These findings indicate that the
conversion of PG to CL can reduce activity of daptomycin in membranes providing low-level
resistance against daptomycin in vivo.
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Figure 2-5: Daptomycin activity across concentrations and liposome content a-f, The y-axis
plots the % activity of varying concentrations of daptomycin based on absolute fluorescence that is
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normalized to the fluorescence achieved by the addition of triton X-100. a-e, The x-axis shows the
type of liposomes tested, which include 1:1 equimolar ratios of PG, PA, or CL to PC and a control
liposome made entirely of PC. f, the x axis indicates the concentration of daptomycin added to the
different liposome compositions. g, Relation of % activity of 35 g/ml of daptomycin based on
absolute fluorescence that is normalized to the fluorescence achieved by the addition of triton X-100
(y-axis) to the % PG content of the liposome tested with PC contributing the remainder of the
required lipid to reach 100% composition (x-axis). Daptomycin activity against liposomes is
correlated with MIC values for WT and daptomycin resistant bacterial isolates where the % PG
content is known. Statistical analysis was performed with 1-way anova and every column was
means compared, p  0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****).

2.3.6 CFLSA Indicates PG Concentration Predicts Daptomycin Activity in
vivo
We found that daptomycin bactericidal activity is correlated with the percent composition
of PG in the membrane. Liposomes with 0%-50% PG were generated as above and daptomycin’s
activity against those liposomes were tested at a consistent 35 µg /ml daptomycin. At or above
20% PG composition, daptomycin did not show a significant change in activity (Figure 2-5g).
This observation directly maps to daptomycin’s in vivo bactericidal activity as measured by MIC
across a number of bacterial species. B. subtilis, C. striatum, and S. aureus strains with 30-50%
membrane PG40,102,103 content have MICs ≤ 1 µg/ml daptomycin. Below 20% PG content,
daptomycin’s activity drops precipitously, both in vitro and in vivo. Daptomycin resistant B.
subtilis with a PG content of 10% showed a 27-fold increase in MIC40. This is recapitulated with
our artificial liposomes where equivalent daptomycin reduction results in 3.66-fold decrease in
carboxyfluorescein-based fluorescence (Figure 2-5g), indicative of a loss in daptomycin activity.
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When membrane PG composition is ≤ 5%, daptomycin’s activity is indistinguishable from
complete absence of PG in the artificial liposome. In HLDR C. striatum, which has 0% PG in its
membrane we see a ≥4000 increase in MIC28,102 and our data shows a 13.5-fold decrease in
carboxyfluorescein fluorescence when the liposomes have < 5% PG. Thus, the percentage
composition of PG relative to other membrane lipids is predictive of daptomycin susceptibility
and activity both in vivo and in vitro. It also suggests that the CFLSA in vitro model is an
effective method of studying daptomycin’s interactions with membranes.

2.4 Conclusions
C. striatum is an emerging, commensal, opportunistic pathogen that has the potential to
cause widespread drug-resistant infections. The rapid adaptive evolution of loss of function
pgsA2 (PG synthase) mutations which result in the significant loss or removal of membrane PG
are necessary and sufficient for high-level daptomycin resistance in C. striatum, which lead to
catastrophic daptomycin treatment failure in patients. No additional genomic or transcriptomic
compensation mechanisms are evident in the evolved HLDR phenotype. The HLDR mutants
also have no changes in cell wall thickness, cell surface charge, conversion of PG to cardiolipin,
or

membrane

shape—mechanisms

previously

implicated

in

lower-level

daptomycin

resistance30,31,33-36,42,43,99,104-107. Rebalancing of membrane composition to include more PI in the
absence of PG as observed by lipidomic profiling likely results in membrane stability. C.
striatum’s ability to completely remove PG from its membrane, with simple loss-of-function
point mutations in PG synthase, further demonstrates that PG is the in vivo and in vitro target of
daptomycin. The remarkable ability of C. striatum to remove a previously presumed necessary
membrane phospholipid could make C. striatum an ideal model for developing new Grampositive antibiotics like daptomycin and studying the potential for resistance to develop.
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2.5 Methods
2.5.1 Whole Genome Sequencing and Comparison
We sequenced eight sets of C. striatum strains before and after emergence of high-level
resistance to daptomycin. Isolates were sequenced using the Illumina Hi Seq 2500 platform,
generating 101bp paired-end reads. One case of resistance emergence occurred in a patient
bloodstream while the remaining strains evolved resistance during in vitro selection. We used the
original susceptible patient isolate as our reference strain and assembled this genome de novo
using SPADES108. This reference genome was annotated using the Prokka v1.12 and the Pfam
database109. We assembled the remaining 15 genomes by mapping to this reference using
bowtie2110. We identified Single Nucleotide Polymorphisms (SNPs) between the resistant strains
and their respective susceptible controls using Pilon.
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The effects of these mutations were

predicted using SNPeff90. All of the genes annotated in the reference genome were clustered by
predicted metabolic function using Blast2Go112. Genes with predicted loss of function mutation
were annotated on this metabolic map. pgsA2 was the only gene with biosynthetic function
predicted to contain loss of function mutations in more than one case of HLDR (in fact, pgsA2
loss of function mutations were found in all cases of resistance). 33 other non-synonymous SNPs
were detected across all eight strain pairs. Only eight of these SNPs were in genes predicted to
affect biosynthetic processes. After clustering by Gene Ontology (GO), pgsa2 altering
phospholipid biosynthesis was the only metabolic alteration predicted in more than one case of
resistance. Phyre2 homology modeling92 supported predictions that the pgsA2 mutation in every
resistant strain was loss of function.
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2.5.2 Transcriptomic Methods
We performed transcriptomic profiling of the susceptible and the in vivo evolved resistant
isolate from the original patient in triplicate. Frozen culture was streaked onto CAMHB plus
blood plates and grown overnight for single colony selection and then and inoculated into 50 ml
CAMHB broth and grown overnight. The following day, the cultures were diluted to 0.5
McFarland standard and split into three 100 mL cultures per condition. The diluted cultures were
incubated at 37 °C with shaking for 1 hour. The cells were collected by centrifugation at 200 g
for 15 minutes. The pellets were resuspended in RNAlater (76104 Qiagen) and frozen at -80 until
analysis.
We used bead beating and SDS treatment to disrupt the sample cells, phenol: chloroform
extraction to remove proteins, and alcohol precipitation followed by DNAase treatment to isolate
RNA from the frozen samples. Ribosomal RNA was removed with Ribo-Zero rRNA Removal
Kit (Epicentre). cDNA libraries were generated from the isolated RNA and amplified as
described in Yoneda, Henson et al.94 The double stranded cDNA libraries were sequenced using
the Nextera113 platform to generate at least 7 million 75bp reads from each sample.
Reads from the triplicate susceptible and HLDR samples were aligned to the reference
genome constructed from the index susceptible isolate using cufflinks 114. Differences in
expression between susceptible and HLDR strains were calculated using cuffdiff115. Fold change
was calculated as resistant expression level divided by susceptible expression level. Expression
levels of the control housekeeping genes rpoA and gyrA remained constant in resistant versus
susceptible samples (Fold change 1.02 and 1.00). Significance of changes was calculated using
the beta negative binomial distribution previously described in Trapnell et al.115 using a
significance level of p < 0.05. Expression levels of genes related to lipid biosynthesis are found
32

in Figure 2-2 and Supplemental Figure 2-2. Additionally, genes with greatest fold changes are
found in the Appendix.

2.5.3 Zeta Potential Measurement Methods
We performed surface charge measurement of the susceptible and HLDR resistant strains
using zeta potential116. Frozen culture was streaked onto CAMHB plus blood plates and grown
overnight for single colony selection and then and inoculated into 50 ml CAMHB broth and
grown overnight. The following day, the cultures were diluted to 0.5 McFarland standard and
one 4 ml culture was grown per condition. The diluted cultures were incubated at 37 °C with
shaking for 1 hour. One (1) ml of the culture was placed in a Malvern zeta-sizing cuvette. Zeta
potential (surface charge) was measured using a Zetasizer Nano ZS (ZEN3600) Dynamic Light
Scattering System (Malvern Instruments) and compared between susceptible and HLDR paired
strains.

2.5.4 Lipidomic Methods
We performed comparative lipidomics across all four mutation types. WT and HLDR
matched isolates were grown overnight and diluted to an OD of 1 in 2.5 ml liquid culture in
quintuplicate. Liquid cultures were spun down to the cell pellet and whole cell lipids were
extracted using the Bligh-Dyer method117. Samples were then stored at -20 until the lipids could
be analyzed via liquid chromatography/mass spectrometry (LC/MS). The peak intensities were
normalized to 100 for each lipid with WT or HLDR being the normalizing lipid. The WT lipid
was chosen as the normalizing lipid for PG, and Cardiolipin because they were most abundant in
WT compared to the HLDR isolate. The HLDR lipid was chosen as the normalizing lipid for
CDP-DAG, Glua-DAG and PI because they were most abundant in HLDR compared to the WT
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isolate. Statistical analysis was performed with 1-way anova and every column was means
compared p  0.05 (*), p 0.01 (**), p 0.001 (***), p0.0001 (****).

2.5.5 Carboxyfluorescein Liposome Stability Assay
We performed a liposome disruption assay118 in triplicate to assess the activity of
daptomycin on varying compositions of liposomes. Equimolar ratios of PG:PC, CL:PC and
PA:PC with a PC only liposome control were created using the reverse phase method containing
carboxyfluorescein119. Liposomes were then suspended in a buffer solution and subjected to
varying concentrations of daptomycin from 3.125g/ml-1000g/ml. Fluorescence increase due
to daptomycin as a result of carboxyfluorescein release was measured using a Varian Eclipse
Spectrophotometer with an excitation wavelength of 492 and an emission wavelength of 512.
Daptomycin activity was measured as a function of normalization to 100% release by triton x100. Additionally, to assess PG% on daptomycin activity, PG:PC liposomes were created in
triplicate with varying mole fraction ratios converted to PG% (50%, 40%, 20%, 15%, 10%, 5%
and 0%) and subjected 35g/ml daptomycin. Statistical analysis was performed with 1-way anova
and every column was means compared p  0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001
(****).

2.5.6 Surface Plasmon Resonance
We performed surface plasmon resonance120 in triplicate to assess the binding of
daptomycin on varying compositions of liposomes. In equimolar ratios (1:1) of PG:PC, CL:PC
and PA:PC with a PC only liposome control were created using the reverse phase method 119.
Liposomes were bound to carboxymethyl dextran hydrogel surface sensor chip that was treated
with sphingosine and subjected to varying concentrations of daptomycin from 3.125g/ml34

35g/ml. Baseline, stable liposome and peak daptomycin binding readings were collected.
Daptomycin binding was normalized to liposome binding and presented as daptomycin/lipid
unit. Statistical analysis was performed with 1-way anova and every column was means compared p
 0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****).

2.5.7 Accession Number
All nucleotide sequences generated during this study have been uploaded to NCBI under
BioProject Accession: PRJNA420593.

2.6 Supplemental Figures and Tables

Supplemental Table 2-1: Available C. striatum isolates Isolate naming convention: W = WT,
R = Resistant, P = Isolated from a patient, E = Evolved from a patient isolate in culture under
daptomycin selection, # = Different isolate source, (a,b,c) = Isolate from same patient collected
at different time points. All isolates’ genomes were sequenced. WP1a was used as the reference
genome. All other genomes were mapped to this genome and SNPs found in the resistant and not
the susceptible isolate from each pair were analyzed further. Transcriptomics was performed on
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WPIa and RP1b. Lipidomics was performed on the WT and resistant matched pairs of:
WP1a:RP1b, WP1c:RE1c, WP2:RE2, WP5:RE5.

Supplemental Figure 2-1: Nonsynonymous mutations in biosynthetic pathways SNPs were
clustered by functional category (using gene ontology). We found that pgsA2 was the only gene
related to cellular biosynthetic function mutated with the exception of 8 additional mutations
observed only in the in vivo evolved isolate. These mutations are consistent with the longer
evolutionary time (17 days) experienced by the isolate between susceptible and resistant states,
in contrast to the only 24 hours of in vitro evolution.

36

Supplemental Figure 2-2: Phosphatidylinositol lipid biosynthesis pathways The lipid
synthesis pathways were constructed with KEGG. 8 WT and HLDR isolate paired genomes were
compared and nonsynonymous single nucleotide polymorphisms identified. The metabolites
names and structures are on the left, with key lipids colored in green. R1 represents the 16:0
carbon chain and R2 represents the 18:1 carbon chain. The enzyme nomenclature for each
enzymatic step and their corresponding genes are located next to the appropriate synthesis arrow.
SNP mutations for each enzyme/gene unit are to the far right with the number of mutations out
of the 8 HLDR isolate, unless no mutations were present in any of the isolates. On the left side,
37

black bars indicate the functional completeness of the PI synthesis pathway. WT and HLDR
proceed through the entire synthesis pathway producing PI. The green color of the lipid PI
indicates a 0.65-4.25-fold buildup of that metabolite in the HLDR isolates compared to WT. Fold
change was calculated using (b-a)/a, where ‘b’ is the largest value and ‘a’ is the smallest to
maintain a positive number.

Supplemental Figure 2-3: Structures of the key phospholipids These lipids are critical to
bacterial membrane composition. R1 = 16:0 carbon chain and R2 = 18:1 carbon chain, black
indicates the glycerol backbone, red indicates the phosphate group and green represents the
functional group.
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Supplemental Figure 2-4: Comparison of HLDR and WT lipid membranes and surface
charge a, WP1a and RP1b isolates were imaged with transmission electron microscopy after 1 hour
with or without the addition of 10g/ml daptomycin. WP1a without daptomycin and RP1b with and
without daptomycin show no membrane irregularities, while WP1a with daptomycin shows
membrane blebbing and disruption. b, all available WT and HLDR isolate pairs were checked for
surface membrane charge changes. Charge was not indicative of HLDR and the range of surface
charge between the most and least negative WT and HLDR isolates were not significant, while there
was significant variability in charge for both WT and HLDR when compared within MIC group.
Statistical analysis was performed with 1-way anova and paired means analysis, p  0.05 (ns), p 
0.05 (*), p  0.01 (**), p  0.001 (***), p  0.0001 (****).
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Chapter 3
Impact of Amoxicillin/Clavulanate followed
by Autologous Fecal Microbiota
Transplantation on Fecal Microbiome
Structure and Metabolic Potential
Collaboration Statement
This work is the result of collaboration between Christopher Bulow, Amy Langdon,
Tiffany Hink, Meghan Wallace, Kimberly A. Reske, Sanket Patel, Xiaoqing Sun, Sondra Seiler,
Susan Jones, Jennie H. Kwon, Carey-Ann D. Burnham, Gautam Dantas, and Erik R. Dubberke
for the CDC Prevention Epicenter Program. C.B. and A.L. designed and performed experiments,
analyzed data and wrote the manuscript. T.H., M.W., K.A.R., S.P., X.S., S.S., and S.J. performed
experiments and analyzed data. J.H.K., CA.B., G.D. and E.R.D. designed experiments, analyzed
data, and wrote the manuscript.

3.1 Abstract
Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce but
autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO
expansion. AutoFMT involves banking one’s feces during a healthy state for later use in
restoring gut microbiota following perturbation. This pilot study evaluated the effect of autoFMT
on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic
capacity after exposure to amoxicillin-clavulanic acid (amox/clav). Ten healthy participants were
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enrolled. All received five days of amox/clav. Half were randomized to autoFMT, derived from
stool collected pre-antimicrobials, by enema and half to saline enema. Participants submitted
stool samples pre- and post-amox/clav and enema and during a 90 day follow-up period. Shotgun
metagenomic sequencing revealed taxonomic composition, resistance gene content, and
metabolic capacity. Amox/clav altered significantly altered gut taxonomic composition in all
participants (n=10, p<0.01); however, only three participants exhibited major changes at the
phylum level following exposure. In the cohort as a whole, beta-lactamase genes were enriched
following amox/clav (p<0.05) and predicted metabolic capacity was significantly altered
(p<0.01). Species composition, metabolic capacity and beta-lactamase abundance returned to
pre-antimicrobial exposure state seven days after either autoFMT or saline enema (p>0.05,
compared to enrollment). Alterations to microbial metabolic capacity occurred following
antimicrobial exposure even in participants without substantial taxonomic disruption, potentially
creating open niches for pathogen colonization. Our findings suggest that metabolic potential is
an important consideration for complete assessment of antimicrobial impact on the microbiome.
AutoFMT was well tolerated and may have contributed to phylogenetic recovery.

3.2 Introduction
The spread of multidrug resistance among pathogenic organisms has rendered many
treatment options ineffective. The World Health Organization has described the situation as the
dawn of a post-antimicrobial era4. The human gut serves as a reservoir for many resistant
organisms and their resistance genes, and this can lead to infection in the colonized host and
transmission of resistance between commensals and pathogens 5-11. Once established in the gut,
antimicrobial resistant bacteria can persist for extended durations even in the absence of
additional antimicrobial exposure6-12. Novel therapeutic approaches are essential to limit or even
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reverse colonization with resistant organisms and the associated risk of infection and
transmission between hosts.
Despite the growing antimicrobial resistance threat, there are no established methods to
effectively reverse the effects of antimicrobial exposure on commensal or pathogenic bacteria.
Several strategies have been proposed for mitigating the threat of resistance but each carries risk.
For example, using non-absorbable broad-spectrum antimicrobials such as rifaximin has may
confine exposure to the gut and prevent systemic resistance selection57. However, this practice
still leads to resistance selection in the gut and allows opportunistic pathogens to gain access in
this critical body habitat58.
A healthy fecal microbiome defends against pathogen and MDRO invasion through
colonization resistance66. Fecal microbiota transplantation (FMT) has been proposed as a method
of restoring the microbiome to a healthy state after treatment with antimicrobials 67. By displacing
infectious or resistant microbes, the new community can restore species diversity, antimicrobial
susceptibility, and colonization resistance67. FMT from healthy allogeneic donors (alloFMT) has
been remarkably successful in treating Clostridium difficile infection (CDI)67,68. Some studies
indicate patients who receive alloFMT for CDI may have a reduction in MDROs in feces as well
as infections69-75. However, this approach has been found to inadvertently allow transmission of
resistance genes from donor to recipient76. Donor feces may also transmit pathogens or
pathobionts which are being asymptomatically harbored by the allogeneic donor. Additionally,
microbiota structure varies significantly between individuals and a poor donor-recipient match
may lead to dysbiosis or FMT failure77-80. Studies to date of the effects of FMT on the
microbiome have primarily relied on 16S ribotype-based analyses of bacterial taxonomic
composition and diversity81-84. While such studies have been transformative in demonstrating
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how well taxonomic compositions match between FMT donors and recipients over time, they are
generally not designed to illuminate functional changes in the microbiome 83,84. Accordingly,
complementary approaches are required to enable a higher resolution understanding of the
impact of FMTs on the composition, dynamics, and transmission of resistance genes and
metabolic capacity encoded by the microbiome.
Autologous fecal microbiota transplantation (autoFMT) is method that could potentially
restore the gut to a healthy state while avoiding the risks of donor resistance genes and donorrecipient mismatch. AutoFMT involves storage of a healthy person’s fecal material for later use
to restore the gut microbiota after perturbation, such as antimicrobial use. Bolstering the
commensal microbiome by autoFMT following exposure to antimicrobials may be effective at
combating colonization with MDROs71. AutoFMT is predicted to have a more desirable safety
profile compared to alloFMT because the feces originated from the participant and was collected
during a healthy state. The purpose of this study was to evaluate the effects of five days of
amoxicillin/clavulanate (amox/clav) on microbiome taxonomic composition, resistance gene
content, and predicted metabolic capacity and the effectiveness of autoFMT versus placebo in
microbiome restoration.

3.3 Results
3.3.1 Enrollment
Ten healthy participants were enrolled in the study; participant characteristics are given
in Table 1. Two participants experienced adverse events >30 days post enema: one patient was
treated with antimicrobials for an ear infection, and the second was diagnosed with H. pylori
infection and treated with antimicrobials. Neither infection was determined to be related to
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amox/clav, autoFMT, or saline enema. There was no difference between study groups in the
number of bowel movements per day post-enema or in bowel movement consistency post-enema
as measured by Bristol stool type (Mann-Whitney U, p>0.05 for all).
Variable

N (%)

Age (median [range])

31 (24 – 57)

Female

6 (60)

Non-white

1 (10)

BMI
Underweight

1 (10)

Normal

3 (30)

Overweight

3 (30)

Obese

3 (30)

Preexisting medical condition

5 (50)a

Smoker (former or current)

0 (0)

Alcohol use
Current

8 (80)

Former

1 (10)

Never

1 (10)

Special diet

1 (10)b

Diarrhea in the past year

5 (50)

Constipation in the past year
2 (20)
a
Table 3-1: Demographics of study population (N=10) Hysterectomy (2), migraine headaches,
mild hearing loss, history of sports injuries, arthritis, history of back surgery, history of ulcer,
history of knee surgery, thyroid partial bVegan plus fish

3.3.2 Taxonomic Compositional Analysis
Among healthy volunteers (n=10), five days of amox/clav resulted in a significant
taxonomic shift from the enrollment composition as measured by Bray-Curtis distance (p<0.01).
The taxonomic composition across all subjects and time points is visualized in Figure 3-1. Both
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the autoFMT and saline groups returned to baseline taxonomic composition by seven days posttreatment (Bray-Curtis distance to enrollment, p>0.05).
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Figure 3-1: Taxonomic composition Taxonomic composition over time was determined by (a)
metagenomic sequencing and (b) qualitative culturomics. (c) Shannon index of diversity was
calculated using species data from metagenomic sequencing. Species composition was
significantly different after amox/clav by type II Adonis test of Bray-Curtis distance (p<0.01).
The most obvious change post amox/clav was a Proteobacteria bloom in subject 8. Numbers
preceded by ‘S’ at the top of columns indicate participant identification number.
Major taxonomic diversity reduction (Shannon index change of at least -1) occurred in
three of 10 participants. Two of these shifts (in participants 5 and 8) occurred immediately
following amox/clav. A bloom in Bacteroidetes and reduction in Actinobacteria and Firmicutes
contributed to the diversity loss in Participant 5. A Proteobacterial bloom and loss of
Bacteroidetes and Actinobacteria appeared to drive diversity reduction in Participant 8. Both
participants were randomized to the autoFMT treatment group. Additionally, participant 4
experienced a reduction in diversity due to loss of Proteobacteria and Actinobacteria seven days
after autoFMT treatment. In each of these three cases, diversity was restored by the next
timepoint (Shannon index within 0.5 of pre-shift value and restoration of reduced phyla).

3.3.3 Resistance Gene Analysis
The resistance genes detected by metagenomic sequencing included a wide range of
common resistance genes. The resistance genes found across the most participants were
tetracycline destructases121,122 and efflux pumps, but the total number of copies of resistance
genes was dominated by beta-lactamases. The beta-lactamases were also the mechanistic
category that showed most reaction to treatment by amox/clav. As expected, the number of betalactamases significantly increased in the study cohort after exposure to amox/clav (p=0.0017),
while the count of non-beta-lactamase antimicrobial inactivation resistance genes was not
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enriched (Figures 3-2 and 3-3). Beta-lactamase gene levels returned to baseline (not significantly
different from enrollment level) in both the saline (p>0.05) and autoFMT (p>0.05) groups.

Figure 3-2: Beta-lactamase gene abundance Beta-lactamase genes were significantly enriched
after amox/clav (two-tailed t-test, p=0.0017). Participants randomized to autoFMT (red) and
saline (grey) both returned to baseline by day 90.
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Figure 3-3: Resistance gene enrichment after amox/clav Enrichment of resistance genes after
amox/clav was determined by comparing normalized counts (RPKM) post amox/clav to
enrollment. Genes are grouped by resistance mechanism. Beta-lactamases (black) were most
enriched and formed a majority of the antibiotic inactivation enzymes enriched. Efflux pumps
were also enriched and functional metagenomic selections suggest co-occurrence of betalactamases and efflux pumps on a mobile element.
Additionally, functional metagenomic selections also provided information about gene
co-occurrence. Genes encoding beta-lactamase CblA and an efflux pump from the AcrB family
co-occurred on 22 different functional metagenomic contigs in eight different selections. Twelve
such co-occurrences had exactly 114 bp between the genes, suggesting a conserved multi-gene
cassette.
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3.3.4 Metabolic Capacity Analysis
Metabolic capacity of the microbiome shifted significantly following amox/clav, even
when subjects with broad phylogenetic differences post amox/clav (participants 5 and 8) were
excluded. In order to assess metabolic perturbations, we structured an index of metabolic
capacity (IMC) from the metagenomic sequencing data. Genes with metabolic functions were
grouped into 37 functional categories. Principal component analysis of IMC (Figure 3-4)
demonstrated an effect of amox/clav on metabolic capacity. IMCs of post-antimicrobial samples
cluster apart from baseline IMCs. The Bray-Curtis distance between baseline and postantimicrobial IMCs was significantly different by type II Adonis (p<0.01). This remained true
when we excluded participants with obvious taxonomic shifts at these time points (5 and 8) to
control for intrinsic metabolic differences between phyla (p<0.01). Additionally, both saline and
autoFMT groups returned to baseline composition (not significantly different from enrollment)
by day seven post treatment (p=0.99 and p=0.84 respectively).
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Figure 3-4: Index of metabolic capacity Principal component analysis (PCA) of metabolic
pathway data (IMC) from participants without obvious taxonomic disturbances (all participants
excluding 5 and 8). IMC was derived from metagenomic sequencing data. Normally distributed
confidence ellipses are shown. Post amox/clav samples have significantly different IMCs than
enrollment samples by type II Adonis test of Bray-Curtis distance (p<0.01). This is true with or
without participants 5 and 8. IMC returned to baseline state by 90 days with saline or autoFMT
at similar rates.
Each metabolic category comprising the IMC was tested for contribution to the difference
between enrollment and post amox/clav IMC using a Random Forest model. Thirteen of the 37
metabolic categories comprising the IMC drove the change in metabolic capacity from
enrollment to post amox/clav. Each of these metabolic pathway categories was enriched postamox/clav. Factors and their relative contribution are found in Supplemental Figure 3-1 and are
ranked according to their contribution to this difference in Supplemental Table 1. AutoFMT did
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not affect IMC differently than the saline control. IMC returned to baseline state by 30 days with
saline or autoFMT. Saline or autoFMT did not result in different rates of return to baseline IMC.
We found significant differences between individual participants’ IMCs when all time points
were compared by type II Adonis (p<0.01).

3.4 Conclusions
This pilot study evaluated the impact of amox/clav on the taxonomic composition,
resistome, and metabolic potential of the microbiome, and whether autoFMT could reverse any
changes. Analysis of antimicrobial perturbation of the gut microbiome is complicated by the
wide variation between baseline taxonomic composition of healthy guts123,124, Additionally,
while antimicrobial use has been previously demonstrated to reduce species diversity and cause
diarrhea, the specific taxonomic changes observed vary greatly by individual123.
Despite the dramatic and rapid perturbations observed acutely following antimicrobial
exposure, longer-term robustness and resilience has been observed in prior reports123-126. Most
pilot studies and case reports after amoxicillin or ciprofloxacin indicate return to baseline by two
months after exposure123-126. However, while overall diversity and structure may be restored,
some species remain missing. These analyses have been limited by resolution of 16S rRNA
sequencing data and have been unable to detect resistance and metabolic genes. These factors
may play critical roles in determining the robustness of the restructured microbiome to
antimicrobial perturbation and pathogen invasion. Using shotgun sequencing we tracked
resistance and metabolic genes not detectable in previous 16S rRNA analyses of taxonomy.
Among healthy volunteers, five days of amox/clav exposure (875 mg BID) led to
significant taxonomic shifts (p<0.01), beta-lactamase gene enrichment (p=0.0017), and predicted
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metabolic capacity alteration (p<0.01). Interestingly, only two participants demonstrated obvious
phylum-level taxonomic perturbation of the type readily detected by traditional analysis.
However, amox/clav led to enrichment of 13 metabolic gene categories and significant alteration
from enrollment. This significant shift in metabolic capacity was observed even in the absence of
phylum level differences. Previous work has demonstrated that metabolic pathways are more
conserved within individuals than phylogenetic structure127. The disruption of these pathways
observed here may be more important than taxonomic alterations when predicting acquisition
and/or proliferation of an MDRO.
This study’s limitations included small sample size and limited taxonomic perturbation
following amox/clav. In addition, the most obvious taxonomic shifts occurred in participants
randomized to autoFMT. These factors limited assessment of autoFMT’s effects on taxonomic
restoration. However, this provided an opportunity to assess metabolic perturbation in the
absence of broad taxonomic shifts. Small sample size limited our ability to assess the
implications of the observed shift in metabolic capacity. Future work is necessary to explore
perturbations caused by more disruptive antimicrobial regimens and the ability of autoFMT to
restore gut phylogeny.
Despite these limitations, this study contributed to our understanding of the gut
microbiome in several important ways. This study supports the concept of the healthy
microbiome’s resilience following perturbation. AutoFMT was found to be safe and well
tolerated, with no adverse events. By seven days following amox/clav phylogeny, beta-lactamase
content, and predicted metabolic capacity returned to baseline.
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Most strikingly, this study demonstrates the importance of assessing gut metabolic
potential which was significantly altered even in the absence of taxonomic shifts. This shift in
metabolic capacity can only be detected using shotgun sequencing or metabolite profiling.
Further work is necessary to determine the implications of this shift in metabolic capacity on risk
of MDRO colonization and host metabolism.

3.5 Methods
This was a prospective, randomized controlled pilot study (NCT 02046525) to determine
the effect of autoFMT on the intestinal microbiome versus placebo (saline enema) after five days
of amox/clav, administered at 875 mg twice per day. The study participants and investigators
were blinded to the treatment assignment until after all analyses were completed. This study was
approved by the Washington University School of Medicine Human Research Protection Office.
Written informed consent was obtained from all study participants

3.5.1 Study Participants
Ten healthy volunteers were recruited to participate. Written informed consent was
obtained from all study participants. Inclusion criteria included being generally healthy and
between 21-70 years of age. Exclusion criteria included a history of allergic reaction to betalactam antimicrobials or contraindications to amox/clav; any non-topical antimicrobial exposure
or tube feeds as a primary source of nutrition in the six months prior to enrollment; pregnant or
risk of becoming pregnant during the study period; gastroenteritis in the last three months; any
non-elective hospitalization in the previous 12 months; incontinent of feces; prior resection or
alteration of the stomach, small bowel, or colon; unwillingness to receive an enema or FMT;
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known colonization with an MDRO; anticipated change in diet, medications, or elective surgery
during the study period; or a history of an intestinal disorder.

3.5.2 Study Procedures
Participants submitted stool samples to investigators at enrollment, immediately postamox/clav, and at days 1, 7, 30, and 90 post-enema (saline or autoFMT). Once the preantimicrobial specimen was obtained, the participant was instructed to take five days of
amox/clav at 875 mg twice daily (BID). Participants were requested to return the bottles of
amox/clav to confirm all doses had been taken. The participant was then randomized in a 1:1
fashion to 100 mL of placebo (non-bacteriostatic saline) or autoFMT product. The autoFMT
product was thawed overnight at room temperature. The study enema was administered 24 to 48
hours after the last dose of amox/clav. In order to maintain blinding of the study participant, the
study enema was delivered to the study clinic in an opaque bag, and the participant was
instructed to not turn around when the enema was being prepared and administered. A vial of the
participant’s autoFMT product was opened in the room, regardless if randomized to placebo or
autoFMT, prior to preparing the enema for administration in order to prevent the participant from
attempting to guess which study group she or he had been assigned to based on the odor during
the procedure. The investigators doing the sequencing work remained blinded to the study group
until after the sequencing was completed.

3.5.3 Fecal Processing
Participants were provided with sealable feces collection devices. After the participant
collected a bowel movement, samples were delivered within 2 hours of collection. Upon receipt,
the feces was immediately processed and 1.5g was reserved for feces culture, 1 g for Clostridium
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difficile culture, approximately 23g for feces pulverization and sequence-based analyses, and the
remainder of the subject’s first sample was used to prepare the FMT product.

3.5.4 FMT Product Preparation
To prepare the FMT product, the remaining feces was weighed and transferred to a sterile
container. Non-bacteriostatic saline was added to the feces in a volume of twice the weight of the
feces. A sterile spatula was used to emulsify the mixture for 3-5 minutes. Then the mixture was
allowed to rest for five minutes. The feces/saline mixture was then poured through a stainless
steel strainer to remove large particulate matter. Four 2 mL aliquots were frozen for genomic
analysis. The remaining filtrate was drawn into 60 mL syringes (50 mL filtrate each, up to four
syringes total). If the patient was randomized to saline, two 60 mL syringes were filled with nonbacteriostatic saline. The filled syringes and aliquots were stored at -80 °C.

3.5.5 Quantitative Culturomics
Fresh feces (1.5g) was added to an equal amount of 1X PBS and mixed thoroughly.
Immediately, six ten-fold serial dilutions were made from the homogenized specimen. 10ul and
100ul of the 1/10 and 1/100 dilutions were plated to two each of the following media: TSA II
with 5% sheep blood (BAP, BBL BD, Franklin Lakes, NJ), Columbia Colistin Nalidix Agar with
5% sheep blood (CNA, BBL BD), MacConkey (MAC, BBL BD) and Chocolate agar (CHOC,
BBL BD). The BAP and CHOC were incubated at 35⁰C in CO2. The CNA and MAC were
incubated at 35⁰C in air. The plates were read at 24h and 72h. 10 µL and 100 µL of the 1/103
and 1/106 dilutions were plated to two each of the following media: Brucella Blood agar (BBA,
Anaerobe Systems, Morgan Hill, CA), Bacteroides Bile Esculin agar (BBE, Anaerobe Systems),
Laked blood with kanamycin and vancomycin (LKV, Anaerobe Systems), cycloserine-cefoxitin
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fructose agar with horse blood and taurocholate (CCFA_HT, Anaerobe Systems), and
phenylethyl alcohol blood agar (PEA, Anaerobe Systems). These plates were incubated at 35⁰C
anaerobically for seven days. The plates were read at 48 h, 4-5 d, and 7 d. 1 g of fresh feces was
processed for culture of C. difficile, as previously described128.
All growth was observed and recorded semi-quantitatively. All distinct colonies were
identified using VITEK MS IVD v2.0 MALDI-TOF MS (bioMerieux). For any isolate that was
not identified, a Gram stain was performed. All isolates were stored in TSB with glycerol at 80C.

3.5.6 Metagenomic DNA Extraction and Sequencing
Metagenomic DNA was extracted from 0.5g of feces via phenol-chloroform for each
sample as previously described.72 DNA from each sample was sheared to 500–600 bp using the
Covaris E220 sonicator (intensity, 4; duty cycle, 10%; cycles per burst, 200; treatment time, 75 s;
temperature, 4 °C; sample volume, 130 µL). The sonication product was purified with the
Qiagen PCR Purification Kit and eluted in 63 µL nuclease-free water (pre-warmed at 50⁰C)
End repair and barcode ligation reactions were performed in triplicate for each sample.
End repair was performed in a Bio-Rad thermocycler using the reagents: 2.5 µL T4 DNA ligase
buffer with 10mM ATP (10X) (NEB B0202S), 1 µL dNTP (1mM), 0.5 µL T4 Polymerase(NEB,
M0203S), 0.5 µL T4 PNK (NEB M0201S), and 0.5 µL Taq Polymerase (NEB, M0267S).
The barcode ligation reaction was performed by adding 2.5 µL of unique sequencing
barcode at 1uM to 500ng of end-repaired DNA. 0.8ul of T4 DNA ligase (NEB, M0202M) was
incubated with the barcode and sample DNA mixture in a Bio-Rad thermocycler. Following
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barcode ligation, samples were pooled into groups containing 6 barcodes. Pools were purified
using the Qiagen PCR Purification Kit and MinELute columns and eluted in 15ul of EB.
Fragment size selection was performed using a Use 0.5 TBE 1.5% agarose gel and
visualized with SYBR Safe DNA stain. Barcoded DNA fragments sized 400-900bp were cut
from the gel and purified with the Qiagen Gel Extraction Kit and MinElute columns and eluted
in 12 µL Buffer EB. 2 µL of the eluted mixture was used for PCR enrichment of size selected
products. The enrichment reaction was prepared as follows: 12.5ul 2X Phusion HF Master Mix,
9.5 µL Nuclease-free water, 1ul Illumina PCR Primer Mix (F+R) (10uM), and 2 µL Gel-purified
DNA. The reaction was performed in a Bio-Rad thermocycler using the program: 17 x [ 98C
30sec (0:30), 65C 30sec (0:30), 72C 30sec (0:30)] 72C 5min, 4C forever.
Size selection of the enriched products was performed using a Use 0.5 TBE 1.5% agarose
gel and visualized with SYBR Safe DNA stain. Fragments sized 400-900bp were cut from the
gel and purified with the Qiagen Gel Extraction Kit and MinElute columns and eluted in 15 µL
of EB. DNA concentration was quantified using a Qbit fluorometer and all samples pools were
combined at equal concentrations for sequencing. Prior to sequencing, pooled fragment size was
assessed with a BioAnalyzer trace and barcode read distribution was assessed using a spike-in
run on the Illumina sequencing platform.
To generate metagenomic sequencing reads, the Illumina NextSeq platform was used
with the high output kit and settings to generate a minimum of 400 million paired-end reads per
run. In total 70 samples were sequenced at least 1 million reads per sample to allow microbiome
and resistome analyses. The depth of 1 million reads was established using previous studies of
the gut microbiome129-131.
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paired-end

shotgun

metagenomic

sequence

reads
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demultiplexed by barcode. Reads without exact match to barcode were discarded. The remaining
reads were quality filtered using Trimmomatic v0.35 and parameters optimized by the Dantas lab
(seed mismatches: 2, palindrome clip threshold: 30, simple clip threshold: 10, min Adapter
length: 1, keep both Reads: TRUE, window size: 4, required quality: 20, leading: 10, trailing: 10,
min length: 60).

3.5.7 Microbiome Taxonomic Composition Prediction
Taxonomic composition was determined by comparing unique indicator sequences from
sequencing reads to clade-specific marker genes from approximately 17,000 reference genomes
using MetaPhlAn 2.6.072. Analysis was performed using metaphlan2/2.6.0 with the following
parameters: --blastdb ./metaphlan2/blastdb --input_type multifasta. The difference in species
diversity was calculated using the Shannon index function from the R vegan package. The
difference in species composition was calculated using Bray Curtis distance between samples
and significance was tested with type II adonis.

3.5.8 Resistance Gene Prediction
The metagenomic DNA sequence was analyzed for both known and sequence-novel
antimicrobial resistance genes using functional metagenomic selections and curated resistance
gene databases for resistance gene identification, and ShortBRED for resistance gene abundance
estimation132. To supplement known resistance gene markers available via the well-curated
CARD database, markers from novel, cryptic resistance gene unique to the studied samples were
obtained by performing functional metagenomic selections on bacterial metagenomic DNA
pooled by participant133. Functional metagenomic identification of genes that conferred
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resistance to amox/clav was performed as previously described 65,72,134 by randomly shearing
metagenomic DNA from each pool of feces into fragment libraries. These libraries were cloned
into the natively pan-susceptible host E. coli DH10B using vector PZE21. For each sample, the
host cells containing library fragments were selected against amoxicillin and ampicillin at
concentrations lethal to the untransformed host. Surviving colonies were pooled and the inserted
fragments sequenced via the Illumina MiSeq platform (2x150bp). Sequencing reads were
assembled into contigs with the PARFUMS pipeline135. The contigs were searched for open
reading frames with MetaGeneMark136 and annotated by hmmscan function of HMMER3 137
against the Resfams core database138, Pfams133, and TIGRFAMS133. Resulting annotations were
then hand-curated133 in the following manner: Selections were excluded if >100 contigs were
assembled because this suggests a failure in the assembly or selection since <100 unique
resistance contigs are expected per selection. Within each contig, annotations were ranked by
specificity to the selective agents and lowest E-value with preference given to Resfams
annotations over Pfams or TIGRFAMS. In absence of a clear specific causative gene annotation
(i.e. a beta-lactamase), the two best annotations with <90% overlap were accepted. The
sequences corresponding to accepted annotations were then pooled with known antimicrobial
resistance genes sequences from CARD 2017133. The genes were then quantified in unassembled
metagenomic sequence using the ShortBRED pipeline with a clustering identity of 1.

3.5.9 Metabolic Pathway Prediction
The metabolic potential of the fecal microbial communities was inferred through
functional potential profiling. The presence and abundance of metabolic pathways in the
microbial communities was assessed using HUMAnN2 which maps unassembled shotgun
sequencing reads to functionally annotated species pangenomes in order to predict function 62.
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Default

parameters

were

used

and

details

can

be

found

at:

http://huttenhower.sph.harvard.edu/humann2.
In order to assess metabolic perturbations, we implemented an index of metabolic
capacity (IMC) from the metagenomic sequencing data. To form this index we grouped genes
with metabolic functions into 37 metabolic pathway categories using Gene Ontology (GO)
terms. GO term grouping was performed using ASaiM139 and custom scripts. The ability of the
predicted metabolic capacity to discriminate between sample groups was visualized using
principal component analysis (PCA) and significance was tested using type II adonis of BrayCurtis distance between samples. This test of significance was conducted with and without
participants 5 and 8 to determine whether any difference observed was driven by the large
taxonomic perturbations seen in those participants. Each metabolic category comprising the IMC
was tested for contribution to the difference between enrollment and post amox/clav IMC using a
Random Forest model. This was implemented using the Boruta package in R 140. Factors were
ranked according to their contribution to this difference.

3.5.10 Statistical Analysis
Significance of differences between taxonomic composition at baseline and post
amox/clav was calculated by determining Bray-Curtis distance between the communities and
using a type II adonis with a significance level of p<0.05 with n=10. Significance of differences
between IMC at enrollment and post amox/clav was calculated similarly. Bray-Curtis distance
between IMCs was calculated and a type II adonis with a significance level of p<0.05 with n=10
was used. Because these are permutation tests, iteration cut-offs were set to detect significance
up to p<0.01. Saline and autoFMT treatment groups taxonomy and IMC were compared to
enrollment for return to baseline comparison. Enrichment of beta-lactamase genes in post61

antimicrobial samples relative to enrollment was calculated using a two-tailed t-test and a
significance level of p<0.05. This test was also applied to the comparison between saline and
autoFMT to enrollment baseline.

3.5.11 Accession Number
All nucleotide sequences generated during this study have been uploaded to NCBI under
BioProject Accession: PRJNA446061.

3.6 Supplemental Figures and Tables
Metabolic Category

Mean Importance Score

Decision

lyase activity

4.93

Confirmed

coenzyme binding

4.92

Confirmed

peroxidase activity

4.77

Confirmed

isomerase activity

4.59

Confirmed

transcription factor binding

4.44

Confirmed

signal transducer activity

4.38

Confirmed

oxidoreductase activity

4.17

Confirmed

receptor activity

4.08

Confirmed

kinase activity

3.63

Confirmed

molecular_function

3.46

Confirmed

transferase activity

3.27

Confirmed

antioxidant activity

3.23

Confirmed

vitamin binding

3.10

Confirmed

metal ion binding

2.43

Tentative

pyridoxal phosphate binding

1.81

Tentative

iron sulfur cluster binding

1.47

Rejected

ligase activity

1.24

Rejected

hydrolase activity

1.01

Rejected

electron carrier activity

0.59

Rejected

tetrapyrrole binding

0.72

Rejected

nucleotide binding

0.51

Rejected
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recombinase activity

0.81

Rejected

phosphatase activity

0.45

Rejected

carbohydrate binding

0.44

Rejected

ion binding

0.03

Rejected

transporter activity

-0.17

Rejected

nucleoside triphosphatase activity

-0.36

Rejected

protein binding

-0.29

Rejected

nucleotidyltransferase activity

-0.35

Rejected

nucleic acid binding

-0.28

Rejected

penicillin binding

-0.42

Rejected

catalytic activity

-0.44

Rejected

peptidase activity

-0.37

Rejected

transposase activity

-0.62

Rejected

drug transporter activity

-0.60

Rejected

structural constituent of ribosome

-0.74

Rejected

Supplemental Table 3-1: Ranked features contributing to index of metabolic capacity shift
Each metabolic category comprising the IMC was tested for contribution to the difference
between enrollment and post amox/clav IMC using a Random Forest model. Features are ranked
by their predicted contribution to difference between enrollment and post-amox/clav IMC.
Features predicted to contribute to this difference are marked “Confirmed” while features
predicted to have no effect are marked “Rejected.”
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Supplemental Figure 3-1: Features driving index of metabolic capacity shift Metabolic
features driving differences between enrolment and post amox/clav samples were identified by a
Random Forest model. Participants 5 and 8 were excluded to eliminate factors related to broad
taxonomic differences. Green indicates features predicted to drive differences while red indicates
features predicted to have no effect. Blue boxplots indicate artificial shadow attributes used for Z
score calibration140.
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Chapter 4
Conclusion and Future Directions
4.1 Mechanisms of Daptomycin Action and Resistance
Daptomycin is a broad spectrum antibiotic used to treat severe Gram-positive infections.
Recent reports of high-level daptomycin resistance (HLDR) have raised concern for the
continued clinical utility of this safeguarded drug. While alarming levels of resistance have
emerged in Streptococci44 and Enterococcus faecium19 it is the ability of Corynebacterium
striatum to rapidly transition to HLDR28 that is most dire. C. striatum poses such a serious threat
due to its ability to rapidly and almost completely remove PG (from ~45% to <1%) from its
outer membrane, demonstrated here. Furthermore, this work has shown that this elimination of
PG occurs without additional compensatory genetic, transcriptomic changes. The HLDR mutants
also exhibit no changes in cell wall thickness, cell surface charge, conversion of PG to
cardiolipin, or membrane shape, changes suggested in reports of lower-level daptomycin
resistance30,31,33-36,42,43,99,104-107. PG absence from the membrane is reconciled by increased levels
of PI. Liposome binding assays presented here have demonstrated that PG is the target of
daptomycin and the lipids that remain in the HLDR stains (PA and CL) do not sufficiently
interact with the drug. This work demonstrates C. striatum has the ability to completely remove
PG from its membrane and further establishes that PG is the in vivo and in vitro target of
daptomycin.
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The remarkable ability of C. striatum to remove a previously presumed necessary
membrane phospholipid highlights the importance of testing for resistance evolution in various
species. This is particularly true in the case of lipopeptide antibiotics that target the mutable
bacterial membrane. Further work is necessary to understand the ability of other commensals and
pathogens to remove or reduce PG membrane content.

4.2 Autologous Fecal Microbiota Transplantation
The pilot autoFMT trial presented here assessed the effects of antimicrobials (amox/clav)
on microbiome structure. Unlike previous work which has relied on phylogeny to infer metabolic
and resistance capacity, the shotgun sequencing performed here allowed identification of
particular genes of interest. In particular, the index of metabolic capacity (IMC) structured here
was significantly perturbed following amox/clav treatment. This shift was driven by enrichment
of 13 metabolic gene categories in response to the antimicrobial. This significant shift in
metabolic capacity was observed even in the absence of phylum level differences. This
underscores the importance of directly assessing metabolically linked genes. Previous work has
demonstrated that metabolic pathways are more conserved within individuals than phylogenetic
structure127. The IMC structured here provides a framework for future studies to measure
differences between individuals and following various perturbations. Further work is necessary
to determine the implications of this shift in metabolic capacity on risk of MDRO colonization
and host metabolism.
AutoFMT was found to be safe and well tolerated, with no adverse events. By seven days
following amox/clav perturbations in phylogeny, beta-lactamase content, and IMC were
reversed. It is important to note that both the autoFMT and the saline control group returned to
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baseline resistance gene abundance and IMC. As only two perturbations in phylogenetic
composition after amox/clav were observed and both were randomized to autoFMT, further work
is necessary to determine whether autoFMT reverses such changes or if healthy microbiomes are
capable of re-balancing phylogenetic composition without outside intervention.
This study’s limitations included small sample size and limited taxonomic perturbation
following amox/clav. Approval for future work involving a greater number of healthy
participants has been obtained. The work reported here has demonstrated the importance of
determining metabolic capacity explicitly rather than drawing inferences from phylogeny. Future
work should compare metabolite profiles (e.g. by mass spectrometry) to the metabolic capacity
predicted by metagenomic sequencing. Furthermore, this data should be coupled with host
response factors. The IMC detailed here is an important first step in more acutely predicting the
metabolic capacity of the human gut.

4.3 General Conclusion
To prevent the arrival of a post-antibiotic era4 we must better understand the mechanisms
of action and resistance and collateral effects of antimicrobials. The work described here makes
progress toward understanding how daptomycin, a critical antimicrobial targets bacterial
membranes and how high-level resistance can emerge rapidly in particular species. Furthermore,
this work identifies important post-antimicrobial shifts in gut microbiome metabolic capacity
that would have been overlooked by traditional 16S rRNA analyses. This continuing effort to
understand antimicrobials and their effects is necessary to maintain medicine’s ability to control
bacteria.
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Appendix: MRSA Epidemiology
Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for communityacquired and healthcare associated infections141-143. When compared to their methicillinsusceptible counterparts, MRSA infections carry increased mortality risk and treatment
costs144,145.
Banked MRSA Genomic DNA
A set of 1880 MRSA strains has been collected by Barnes-Jewish Hospital from 20052012146. These isolates were obtained during epidemiological surveillance of the SICU146. The
isolates were obtained by nasal swab and genomic DNA from 504 randomly selected isolates
was available146. 200 samples representing a span of collection years and SCCmec type were
selected for whole genome sequencing.
Sequencing and Genome Assembly
Isolates were sequenced using the Illumina Hi Seq 2500 platform, generating 101bp
paired-end reads. We assembled each genome de novo using SPADES108. 76 genome assemblies
passed the quality control. These genomes were annotated using the Prokka v1.12 and the Pfam
database109.
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Phylogenetic Tree Construction
A pan genome and was constructed and core genome alignment was performed (from the
.gff files generated by Prokka) using Roary147 and the following parameters: << roary -e --mafft p 8 *.gff >>. A phylogenetic tree of resulting from this core genome alignment is shown in
Figure A-1. The 76 isolates clustered into three distinct clades.

Figure A-1: Core genome alignment The 76 core genomes obtained over time in the SICU
cluster into three distinct branches one of which is noticeably distinct in this representation.
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Resistance Gene Annotation
The three distinct clades observed by alignment and phylogenetic prediction did not
correspond to year collected (Figure A-2). This could be the result of three distinct sources of
MRSA entering the SICU (e.g. community, ER, outpatient care facility). To explore these clades
further we mapped SCCmec type and mobile resistance gene abundance to the groups (Figure A2). The top clade was the most phylogenetically distinct from the others and contained an even
mix of SCCmec type IV and II. The middle clade was predominantly type IV (communityassociated strains) and the bottom clade was predominantly type II (hospital-associated strains).
There does not appear to be a difference in resistance transferrable gene carriage between
the groups. Work in progress assesses resistance mutations that are less not transferrable as well
as multilocus sequence type (MLST). Additionally, the genomes will be compared to other
global MRSA genomic datasets to help infer their origin. The five most similar published
genomes to each of the strains will be determined and metadata from these nearest neighbors will
be used to infer origin of each clade. Furthermore, a classifier will be constructed to determine
which genes and metadata features effectively predict clade.
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Figure A-2: Phylogeny with SCCmec type, year, and resistance genes The phylogenetic tree
is annotated by SCCmec type (Roman numerals) and year (Color of Roman numerals: Green is
earliest and purple is latest). Additionally, resistance gene presence (red) or absence (green) is
depicted. The three distinct clades observed in the 76 MRSA isolates did not correlate with year
collected. The top clade was the most distinct and an even mix of SCCmec type IV and II. The
middle clade was predominantly type IV (community associated) and the bottom clade was
predominantly type II (hospital associated).
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Appendix: Extended Data
Chapter 2 Extended Genomic Data
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Table A-1: All SNPs observed Only SNP in all 8 HLDR isolates was in pgsA2
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Chapter 2 Extended Transcriptomic Data
Function
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Table A-2: Increased expression Changes greater in magnitude than 25%
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Table A-3: Decreased expression Changes greater in magnitude than 25%
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